Get in the KNOW
on LA Startups & Tech
XMeet the Startup That Wants To Deliver Ketamine to Your Door
David Shultz
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Ketamine is on the come up in the pharmaceutical world. Once confined to nightclubs and operating rooms, the drug is quickly gaining recognition as a valuable tool for treating mental health disorders including depression and anxiety.
Amid these rising tides, Wondermed has emerged, offering telehealth consultations and, potentially, the ability to deliver the drug right to your doorstep—all while building out a virtual platform and collecting data on how to use the molecule more effectively.
At the moment, the company provides a mail order service for courses of ketamine lozenges to those who’ve been prescribed the drug along with a telehealth software bridge between doctor and patient. Wondermed currently operates in five states — California, Texas, Florida, New York and Connecticut, though it plans to expand to another eight to 10 states in the next two weeks.
In the long run however, its plans are much bigger than being a link between doctors and patients.
“We generate more than 3,000 data points on every patient that comes into the funnel, and actually receives the medication,” says co-founder & Managing Director Jose Aycart.
His company is building out its online platform to collect and analyze patient data and provide mental health support services that may be useful, regardless of whether or not a patient is taking ketamine.
These data show in granular detail how ketamine therapies work. Does the route of administration matter? Does time of day matter? What types of patients are most likely to experience positive outcomes? It’s this data that represents the biggest business opportunity for Wondermed. The specifics of the monetization are still being worked out, but Aycart says it will never sell anonymized patient data to other companies.
Wondermed is in the midst of a seed funding round, targeting $7 million by the end of the month; It’s raised $5.6 million so far.
The company makes a bit of revenue by charging patients for consultations, but in the event that a patient doesn’t wind up using Wondermed’s platform, the consultation fee is refunded. For patients who are prescribed ketamine, the company charges only as much as the drugs cost them ($249 per month, which includes four doses), so neither Wondermed nor the physicians in its employ are incentivized to over-prescribe.
The drugs themselves are supplied by Tailor Made Compounding, a pharmacy in Nicholasville, Kentucky, and Wondermed is working on additional contracts in the pipeline with several other suppliers.
. Wondermed’s transformation comes as ketamine, which has typically been restricted to use as a general anesthetic, is quickly gaining recognition as a valuable tool for treating mental health disorders like depression and anxiety.
“What I’ve found interesting is how rapidly this field has emerged,” says Steven Grant, a drug and addiction researcher who spent 25 years at the National Institute on Drug Abuse and is now retired.
Ketamine is a simple organic molecule that first gained clinical popularity in the 1960s as an anesthetic. It produces a dissociative state in patients and dulls pain. Once in the bloodstream, the molecule travels to the brain where it binds to a protein called NMDA on the surface of neurons. NMDA has a variety of jobs, but it’s best-known for its role in learning, memory, and neuroplasticity—or the brain’s ability to form new pathways between neurons.
While the research into why ketamine is such an effective treatment for depression and anxiety is ongoing, the consensus so far is that the molecule’s power comes from this ability to rewrite or rewire the brain’s circuitry. If you’ve ever had an anxiety attack or a depressive episode, it can often feel like you’re stuck in a mental loop. Ketamine, it seems, offers a way to break that loop.
“It was this idea that you're increasing your neurological connections in the brain,” says Aycart. “You have the opportunity now to spark new forms of thought, new forms of emotion, or even new ideas.”
Unlike selective serotonin reuptake inhibitors (SSRIs) and other traditional drugs used to treat depression, ketamine’s effects are fast-acting—often appearing within minutes or hours of administration—and don’t require taking the drug daily.
“It really is revolutionary, and that’s why now more than ever, people are starting to get access to it, and companies like ourselves are really trying to bring it to people as an alternative form of medicine,” says Aycart.
Grant says the rise of ketamine clinics and telehealth services like Wondermed are likely a net positive because they increase patient access to drugs patients need, but he also has reservations about how the therapies are being applied.
Many of these psychoactive drugs—especially ketamine—are intended to be used in tandem with therapy, or at least under the supervision of a trained professional. Increasing the brain’s plasticity is a valuable tool for breaking out of depressive loops, but unless a professional is there to help the patient settle into a healthier mental pattern, the full benefits may be left on the table.
Wondermed offers a variety of supplementary support and strategies along with the drugs themselves, but taking advantage of these tools is left to the patient’s discretion. Grant would like to see a larger focus on extending and expanding that auxiliary support.
The company says it’s focused on building out the platform’s nonmedicinal mental health strategies—things like breathwork, meditation, music therapy—and adding them to an app. If they can get enough people on board, the eventual plan could be to sell health insights back to patients through a subscription model or something similar. They may even patent their own psychedelic molecules in the future. But all of this is likely quite a ways out.
“What we're trying to do is very new, and the landscape yet hasn't been built out,” says Aycart.
Clarification: This story has been updated to clarify Wondermed's monthly rate for ketamine lozenges.
From Your Site Articles
- Psychedelic Therapies Are Gaining Steam as Attitudes Change - dot ... ›
- Ketamine for Depression Is Now Available by Injection - dot.LA ›
- Ketamine Clinics Are Opening Across Los Angeles - dot.LA ›
- Pasithea Opens a Chic Clinic in Beverly Hills to Administer Ketamine - dot.LA ›
- New Pasithea Ketamine Clinic In Beverly Hills - dot.LA ›
- Pasithea Opens a Ketamine Clinic In Beverly Hills - dot.LA ›
Related Articles Around the Web
David Shultz
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Skeptics once doubted the feasibility of a high-speed rail connecting LA to Las Vegas, but now it's becoming a reality. Perhaps all it takes is the right team to turn the improbable into the possible.
LA County has invested millions to establish itself as a biotech hub, including funding the nonprofit BioscienceLA and its BioFutures program. The county's investments have also created a supportive infrastructure with initiatives like the 20,000-square-foot BioscienceLA office in Culver City, generating significant economic activity and jobs. However, despite these efforts, LA has remained a secondary market for biotech and life sciences due to geographic sprawl and limited supply of life science/biotech space, even though the region boasts significant life science talent.
Life Science Degree Completions by Vacancy Comparison
A leading figure in the biotech scene in Los Angeles is the impressive biotech entrepreneur, Arie Belldegrun. Belldegrun has played a significant role in the successful exits of Agensys, Cougar Biotechnology, and Kite Pharma, which collectively sold for $13.4 billion. An Israeli-born urologist and immunology researcher, Belldegrun has been instrumental in building the biotech sector in Los Angeles. Utilizing proceeds from these exits, he established Bellco Capital, which primarily invests in life science and real estate companies, and co-founded several biotech-focused funds and ventures.
Belldegrun's efforts have culminated in the creation of the California Institute for Immunology and Immunotherapy at the former Westside Pavilion in Westwood, in collaboration with other prominent figures and philanthropists. The 700,000-square-foot property, acquired at the end of 2023, will also house the UCLA Center for Quantum Science & Engineering. “The goal is to build the immunology equivalent of Silicon Valley in Los Angeles,” says UCLA Health CEO John Mazziotta, MD, PhD. The center will hold its own patents and will eventually foster new biotech startups through its incubator and accelerator programs. The initiative has secured $500 million in state funding and plans to raise an additional $1 billion, positioning Los Angeles to become a leading biotech hub alongside regions like the Bay Area, San Diego, and Boston. Despite challenges posed by the city's geographic sprawl, these combined efforts by leaders like Belldegrun and county programs are transforming LA's biotech landscape, fostering a thriving environment for future scientific and commercial successes.
Read moreShow less
Christian Hetrick
Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.
A Strong Finish to 2024 for LA Tech: Crosscut Ventures Leads the Way
11:18 AM | January 03, 2025
🔦 Spotlight
Happy Friday LA!
As we close the book on 2024, Los Angeles has had a remarkable year in tech and venture capital. From groundbreaking funding rounds to industry-defining innovations, the city’s tech ecosystem has showcased its ability to adapt and thrive. Among the year’s final highlights was the announcement that Crosscut Ventures, one of LA’s premier early-stage venture capital firms, has added Jon Ylvisaker as its newest Partner.
Crosscut Ventures’ Bold New Direction
Announced in late December, Jon Ylvisaker’s appointment reflects Crosscut Ventures’ commitment to advancing its focus on the energy transition. Ylvisaker brings decades of experience in driving investments in energy technologies and digital infrastructure. As the founding partner and managing director of Yield Capital Partners, he led investments in startups and established companies shaping the future of sustainability. At Wolfacre Global Management, a Tiger Management hedge fund, he further honed his expertise in supporting impactful climate-focused solutions.
Brian Garrett, Managing Director and Co-Founder of Crosscut Ventures, said, “Jon's extensive experience in climate and digital infrastructure investments, coupled with his impressive track record of bringing groundbreaking technologies to market, makes him the ideal partner to help lead our focus.”
Since its founding in 2008, Crosscut has played a key role in shaping LA’s tech landscape. Ylvisaker’s addition reinforces the firm’s commitment to addressing global challenges like energy transition and sustainability, further solidifying its leadership in venture capital innovation.
What’s Next for LA Tech in 2025
The momentum from 2024 has set the stage for an even bigger year ahead. Entrepreneurs, investors, and innovators in LA are poised to take on new challenges and create meaningful change across industries.
As we step into 2025, we want to thank everyone who helped make 2024 such a standout year. Here’s to another year of progress, innovation, and success. From all of us at dot.LA, Happy New Year!
🤝 Venture Deals
LA Companies
- First Resonance, a company specializing in digital manufacturing software through its ION Factory OS, has raised a $20M funding round led by Third Prime with participation from Blue Bear Capital and others. This brings its total funding to $36M and will be used to accelerate product development, grow its customer base, and enhance support for advanced manufacturing sectors like aerospace, robotics, and clean energy. - learn more
LA Venture Funds
- Finality Capital Partners led a $17M Seed funding round for ChainOpera AI, a California-based company developing blockchain networks for AI-powered agents and applications, to accelerate product development, expand its team and enhance its blockchain and AI integration capabilities. - learn more
LA Exits
- Thirteen Lune, an inclusive beauty e-commerce platform, has been acquired by SNR Capital, marking a significant milestone in the platform's mission to amplify underrepresented beauty brands while fueling its next stage of growth. - learn more
- Ergobaby, a leading brand in juvenile products known for its high-quality baby carriers, has been acquired by Highlander Partners. The acquisition aims to bolster Ergobaby’s growth, expand its product offerings, and strengthen its position in the parenting solutions market. - learn more
Read moreShow less
RELATEDTRENDING
LA TECH JOBS